Latest Insider Transactions at Progyny, Inc. (PGNY)
This section provides a real-time view of insider transactions for Progyny, Inc. (PGNY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Progyny, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Progyny, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 30
2020
|
Lisa Greenbaum EVP, Chief Client Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,228
-24.64%
|
$66,840
$30.04 P/Share
|
Sep 30
2020
|
Lisa Greenbaum EVP, Chief Client Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+30.67%
|
$12,000
$3.96 P/Share
|
Sep 29
2020
|
Peter Anevski CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Indirect |
84,000
-20.0%
|
$2,436,000
$29.3 P/Share
|
Sep 24
2020
|
Lisa Greenbaum EVP, Chief Client Officer |
SELL
Open market or private sale
|
Direct |
869
-14.7%
|
$22,594
$26.77 P/Share
|
Sep 24
2020
|
Lisa Greenbaum EVP, Chief Client Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,131
-16.06%
|
$29,406
$26.73 P/Share
|
Sep 24
2020
|
Lisa Greenbaum EVP, Chief Client Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+22.11%
|
$6,000
$3.96 P/Share
|
Aug 19
2020
|
Kleiner Perkins Caufield & Byers Xiii, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,008,047
-93.48%
|
-
|
Aug 19
2020
|
Kleiner Perkins Caufield & Byers Xiii, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
1,078,340
+50.0%
|
-
|
Aug 19
2020
|
Kleiner Perkins Caufield & Byers Xiii, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
2,797,800
-15.88%
|
-
|
Jul 24
2020
|
Lisa Greenbaum EVP, Chief Client Officer |
SELL
Open market or private sale
|
Direct |
9,005
-64.1%
|
$234,130
$26.95 P/Share
|
Jul 24
2020
|
Lisa Greenbaum EVP, Chief Client Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,995
-33.24%
|
$181,870
$26.79 P/Share
|
Jul 24
2020
|
Lisa Greenbaum EVP, Chief Client Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,000
+43.19%
|
$48,000
$3.96 P/Share
|
May 20
2020
|
Glaxosmithkline PLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,000,000
-39.07%
|
$100,000,000
$25.75 P/Share
|
Jan 22
2020
|
Kleiner Perkins Caufield & Byers Xiii, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
489,038
-84.41%
|
-
|
Jan 22
2020
|
Kleiner Perkins Caufield & Byers Xiii, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
522,904
+47.44%
|
-
|
Jan 22
2020
|
Kleiner Perkins Caufield & Byers Xiii, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,398,900
-14.43%
|
-
|
Jan 07
2020
|
Kleiner Perkins Caufield & Byers Xiii, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
489,038
-89.65%
|
-
|
Jan 07
2020
|
Kleiner Perkins Caufield & Byers Xiii, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
522,904
+48.94%
|
-
|
Jan 07
2020
|
Kleiner Perkins Caufield & Byers Xiii, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,398,900
-12.61%
|
-
|
Oct 29
2019
|
Kleiner Perkins Caufield & Byers Xiii, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
16,902,868
+42.57%
|
-
|
Oct 29
2019
|
Glaxosmithkline PLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
9,821,190
+48.96%
|
-
|